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ABSTRACT
Background Achieving the best possible reperfusion is 
a key determinant of clinical outcome after mechanical 
thrombectomy (MT). However, data on the safety and efficacy 
of intra- arterial (IA) fibrinolytics as an adjunct to MT with the 
intention to improve reperfusion are sparse.
Methods We performed a PROSPERO- registered 
(CRD42020149124) systematic review and meta- analysis 
accessing MEDLINE, PubMed, and Embase from January 1, 
2000 to January 1, 2020. A random- effect estimate (Mantel- 
Haenszel) was computed and summary OR with 95% CI 
were used as a measure of added IA fibrinolytics versus 
control on the risk of symptomatic intracranial hemorrhage 
(sICH) and secondary endpoints (modified Rankin Scale ≤2, 
mortality at 90 days).
Results The search identified six observational cohort 
studies and three observational datasets of MT randomized- 
controlled trial data reporting on IA fibrinolytics with MT as 
compared with MT alone, including 2797 patients (405 with 
additional IA fibrinolytics (100 urokinase (uPA), 305 tissue 
plasminogen activator (tPA)) and 2392 patients without IA 
fibrinolytics). Of 405 MT patients treated with additional IA 
fibrinolytics, 209 (51.6%) received prior intravenous tPA. We 
did not observe an increased risk of sICH after administration 
of IA fibrinolytics as adjunct to MT (OR 1.06, 95% CI 0.64 
to 1.76), nor excess mortality (0.81, 95% CI 0.60 to 1.08). 
Although the mode of reporting was heterogeneous, some 
studies observed improved reperfusion after IA fibrinolytics.
Conclusion The quality of evidence regarding peri- 
interventional administration of IA fibrinolytics in MT is 
low and limited to observational data. In highly selected 
patients, no increase in sICH was observed, but there is large 
uncertainty.
INTRODUCTION
Achieving complete reperfusion is the most important 
modifiable predictor for maximizing the treatment 
effect of mechanical thrombectomy (MT).1–3 Although 
the chances for a clinical benefit are optimal if 
complete reperfusion is attained after the first pass,4 5 
there is a growing body of evidence suggesting that an 
effect of improved reperfusion is still tangible after 
multiple attempts and prolonged procedure time.6–8 
Despite recent technical advances, failed reperfusion 
(Thrombolysis in Cerebral Infarction (TICI) 0/1) is the 
final result of MT in every 10th patient,9–11 and most 
patients treated successfully do not reach complete 
reperfusion (TICI 3).12 13 Treatment options in these 
scenarios are distal MT of thrombus fragments,7 14 
bailout stenting15 or administration of intra- arterial 
(IA) fibrinolytics.16 17
According to a survey by investigators of the German 
Stroke Registry, up to 40% of interventionalists admin-
ister IA fibrinolytics during or after MT on a case- by- 
case basis,18 and a recent US survey described the use of 
IA thrombolysis in 61% of the survey’s responders.19 
The recently published updated American Stroke Asso-
ciation/American Heart Association guidelines state 
that IA fibrinolysis constitutes a reasonable supplement 
to achieve TICI grade 2b/3 results20; however, data on 
the safety and efficacy of IA fibrinolytics as adjunct to 
MT are still scarce.16 17 21 22
In view of clinical equipoise, and with the inten-
tion to inform the planning of potential randomized 
controlled trials, we conducted a systematic review 
and meta- analysis to report on observational data 
comparing safety and efficacy outcomes in patients 
with MT, either additionally treated with IA fibrino-
lytics or best medical management.
METHODS
This study is reported according to the recommen-
dations of the Preferred Reporting Items for System-
atic reviews and Meta- Analyses (PRISMA) reporting 
guideline.23
Protocol and registration
The protocol for this study was published 
before performing the analysis (PROSPERO: 
CRD42020149124).
Study eligibility criteria
Eligible studies included all age groups and all ethnic 
groups reporting on adults (older than 18 years) 
with an acute ischemic stroke and IA fibrinolytic 
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therapy as adjunct to MT treatment of a target large- vessel occlu-
sion. Acute ischemic stroke had to be diagnosed by qualified 
personnel (in an emergency department, stroke center, depart-
ment of neurology, or similar unit) and large- vessel occlusion 
had to be confirmed by pre- interventional imaging (MR angi-
ography/CT angiography or first diagnostic digital subtraction 
angiography runs). Studies had to report symptomatic intracra-
nial hemorrhage (sICH) or adequate surrogates (eg, parenchymal 
hematoma type II according to the European Cooperative Acute 
Stroke Study (ECASS) criteria) in patients treated with second- 
generation MT (aspiration technique or stent- retriever devices) 
with strata of administration of IA fibrinolytics during MT (with 
or without additional IA fibrinolytics, respectively). Fibrinolytics 
considered were (pro)urokinase, alteplase, reteplase and tenect-
eplase. In this manuscript, tPA (tissue plasminogen activator) and 
uPA exclusively refer to alteplase and urokinase, respectively. We 
excluded studies reporting on historical mechanical treatments 
such as balloon angioplasty, guidewire clot disruption or first- 
generation devices, and we did not consider bailout stenting for 
this analysis. Abstracts were included if the authors were able 
to provide the required data for this meta- analysis. Otherwise, 
we included peer- reviewed, original studies only. Since state- of- 
the- art endovascular therapy was used in the last two decades, 
we only considered publications beyond January 1, 2000 for 
analysis. Additionally, we contacted the Principal Investiga-
tors of randomized- controlled trials included in the HERMES 
collaboration,24 if the trial protocol allowed administration of 
IA fibrinolytics in the mechanical thrombectomy arm (ESCAPE 
(Endovascular Treatment for Small Core and Anterior Circula-
tion Proximal Occlusion With Emphasis on Minimizing CT to 
Recanalization Times),25 MR CLEAN (Multicenter Random-
ized CLinical trial of Endovascular treatment for Acute ischemic 
stroke in the Netherlands),26 THRACE (Trial and Cost Effec-
tiveness Evaluation of Intra- arterial Thrombectomy in Acute 
Ischemic Stroke)27). Corresponding authors of the included 
observational studies were contacted to provide the median 
dose of fibrinoloytics and rates of sICH with strata of intrave-
nous thrombolysis (IVT)+MT+IA versus IVT+MT and direct 
MT+IA versus direct MT only. We excluded studies with dupli-
cate data, or no specific strata of patients receiving adjunct fibri-
nolytic therapy. When sICH was the primary outcome of a study, 
but the authors did not report numbers for patients receiving 
additional fibrinolytic therapy, authors were contacted to report 
events of sICH and mortality in patients receiving additional 
fibrinolytic therapy during or after aspiration or mechanical 
thrombectomy. We excluded studies with <10 patients under-
going endovascular treatment.
Data sources and searches
Data for this review were identified via a search on MEDLINE, 
PubMed and Embase, as well as references from relevant arti-
cles using a predefined search strategy formulated according to 
the Population, Intervention, Comparison and Outcome (PICO) 
format search strategy (online supplemental information 1). 
Only articles published in English, French, Spanish and German 
between January 1, 2000 and January 1, 2020 were included.
Study selection
Publications were uploaded into the Covidence online review 
tool. Their relevance was assessed against the predetermined 
inclusion and exclusion criteria by two independent researchers 
(JK and TRM), who screened all titles and abstracts. Forward 
and backward reference searching complemented the database 
searches. Full- text manuscripts were obtained for all studies 
entering full- text review. Any uncertainties about including a 
specific manuscript in the review were resolved by consensus.
Data collection process and data items
Data were extracted into the Review Manager Program (RevMan, 
Version 5.3. Copenhagen: The Nordic Cochrane Centre, The 
Cochrane Collaboration, 2014) by TRM and reviewed by JK. 
Data items included type of study, unadjusted and adjusted odds 
for the primary and secondary outcomes with a description of 
parameters adjusted for, type of sICH scale applied, and pres-
ence of differences in baseline characteristics between patients 
with and without additional IA fibrinolytics within a study. All 
extracted raw frequency counts can be found in the forest plots.
Risk of bias in individual and across studies
We compared data items, outcomes, design strengths and weak-
nesses across the studies. For each study, the risk of bias was 
assessed at the study level using the Cochrane ROBINS- I bias 
assessment tool with study- specific items, and this information 
was incorporated when interpretation of data was given in the 
synthesis.
Outcomes
The main outcome was the occurrence of sICH according to the 
study- specific definition in the acute phase of stroke care (usually 
within 24 hours, see online supplemental table 1 for definition of 
sICH). If not available, other surrogates (eg, parenchymal hema-
toma type II according to ECASS) were considered, because it 
is associated with a high likelihood of neurological deteriora-
tion.28 Secondary outcomes included all- cause mortality at 90 
days, good functional outcome at 90 days (modified Rankin 
Scale (mRS) 0–2), and angiographic effect regarding the addi-
tional administration of IA fibrinolytics. This could be reported 
as frequencies of final TICI score with strata of MT patients with 
and without IA fibrinolytics or dedicated improvement of reper-
fusion analyses after administration of IA fibrinolytics. Successful 
reperfusion was defined as TICI 2b/3. For the summary esti-
mate regarding successful reperfusion, we divided the studies 
into those reporting on patients with the primary intention to 
improve unsuccessful or incomplete reperfusion (high risk of 
reperfusion bias towards poor TICI grades in the IA groups), 
and studies where IA fibrinolytics were mainly applied during or 
before initial stent- retriever deployment or studies in which the 
control group of patients without IA fibrinolytics also consisted 
of patients with unsuccessful or incomplete MT patients (low 
risk of reperfusion bias towards poor TICI grades in the IA 
group). Studies without documented reason for administering 
IA fibrinolytics were rated as unknown risk of reperfusion bias.
Synthesis of results and summary measures
If available and consistent throughout the studies, the 
summary estimates of effect sizes (summarized ORs, and 
adjusted summarized ORs (aOR)) for sICH in MT patients 
with additional IA fibrinolytics as compared with MT patients 
without additional IA fibrinolytics (control patients) were 
calculated using a random- effects model (Mantel- Haenszel 
method). Adjusted ORs were summarized separately, if avail-
able. Heterogeneity was assessed by p value of χ2 statistics 
and I2 which describes the percentage of variability in the 
estimates that cannot be explained by chance.29 We consid-
ered study- level estimates to be heterogeneous if the I2 
statistic was >50%. All p values were calculated by two- 
sided tests and a significance level of 0.05 was used. Visual 
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inspection of the funnel plot was used for the evaluation of 
publication bias. Data analysis was performed using R30 with 
the R package ‘meta’ 4.9–7.31 If available, calculations were 
made for secondary outcomes using the same analysis tools.
RESULTS
The database searches and citation tracking yielded 711 hits, 
of which 447 records were screened as potentially relevant 
after removing duplicates (see online supplemental figure 
1 for PRISMA flow- chart). Reasons for excluding relevant 
publications after full- text review are also shown in online 
supplemental figure 1). In total, five publications met the 
inclusion criteria of reporting the risk of sICH after failed or 
incomplete large vessel occlusion MT in patients receiving 
fibrinolytics and inclusion of a control group receiving no 
fibrinolytics (all non- randomized observational studies). 
We also contacted the main author of a published abstract 
to provide the study data with strata of MT+IA versus MT 
alone.32 In addition, three of the principal investigators of 
recent MT trials allowing for the use of IA fibrinolytics 
provided unadjusted estimates regarding the frequency of 
sICH, as well as mRS 0–2 and mortality at 90 days with 
strata of additional administration of IA fibrinolytics.25–27 
One principal investigator of recent MT trials allowing for 
the use of IA fibrinolytics also provided adjusted estimates 
correcting for age, sex and baseline National Institutes of 
Health Stroke Scale (NIHSS). In summary, nine studies 
reporting on 2797 patients were included.
The characteristics of these six observational cohort 
studies and observational data derived from the three 
included MT trials are shown in table 1. Eight studies 
compared IA tPA with control,16 17 21 22 25–27 32 and one study 
compared IA urokinase with control.33 Rates of sICH were 
available in eight of nine studies, with one study reporting 
rates of parenchymal hematoma type 2 (PH2) only.17 The 
definitions of sICH and comparator groups across studies 
were somewhat heterogeneous, but most studies used a 
compound definition of radiological verification of intracra-
nial hemorrhage together with a neurological deterioration 
of ≥4 points on the NIHSS (see online supplemental table 
1). Nearly all studies were confined to patients with small or 
medium size core infarct volumes and some studies reported 
significant baseline differences between the groups, most 
commonly favoring the group who additionally received IA 
fibrinolytics (ie, younger age, or earlier presentation, see 
online supplemental table 1).
In total, we included 405 cases with additional administra-
tion of IA fibrinolytics (100 urokinase, 305 tPA), and 2392 
controls in the meta- analysis. Of 405 patients receiving 
IA fibrinolytics, 209 were pretreated with intravenous tPA 
(51.6%). Applied median dose of IA fibrinolytics ranged 
from 4–13.25 mg for tPA and was 300 000 U for IA uroki-
nase. In eight studies with available information, reasons for 
administration of IA fibrinolytics consisted of rescue after 
failed MT (TICI0/1, 4/8 studies), incomplete reperfusion 
(TICI2a/b, 5/8 studies), administration during stent- retriever 
deployment at the discretion of the operator (4/8 studies), 
and treatment of emboli to new territories (1/8 studies).
Except for one study,21 follow- up duration was 3 months 
in all studies. The Cochrane ROBINS- I risk of bias assess-
ment for the included studies with adoption of items for 
observational data are summarized in online supplemental 
figure 2. All trials had performance bias due to non- blinding 
of intervention and three trials had attrition bias due to 
incomplete outcome data.
Symptomatic intracranial hemorrhage and mortality
Pooling the results from all studies using the random- 
effects model showed that added IA fibrinolytics compared 
with control were not associated with an increased risk of 
sICH (OR 1.06, 95% CI 0.64 to 1.76; I2=0%) (figure 1). 
Limiting observations to IA tPA only yielded a point estimate 
of OR 1.23 (95% CI 0.67 to 2.26). There was no evidence 
of publication bias on funnel plot analysis (online supple-
mental figure 3). There was no significant heterogeneity 
of the effect of added IA fibrinolytics with strata of IVT 
pretreatment status (IVT+MT+IA vs IVT+MT, OR 1.28, 
95% CI 0.60 to 2.75; and direct MT+IA vs direct MT only, 
OR 1.48, 95% CI 0.71 to 3.11) (figure 2). Additionally, a 
direct comparison of patients treated with IVT+MT+IA 
fibrinolytics versus MT+IA fibrinolytics yielded no evidence 
of a significant difference (OR 1.11, 95% CI 0.43 to 2.87) 
(figure 3).
Figure 1 Forest plot of summary odds ratios for sICH in patients with and without adjunctive administration of IAF during MT. *For Anadani et al 
we used PH2 as sICH surrogate. IAF, intra- arterial fibrinolytics; MT, mechanical thrombectomy; PH2, parenchymal hematoma type 2; sICH, symptomatic 
intracranial hemorrhage; tPA, tissue plasminogen activator; uPA, urokinase.
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Meta regression, limited to five studies reporting on 
median IA tPA dose applied (median dose range 4–10 mg), did 
not provide evidence for heterogeneity or dose- dependency 
regarding the association of MT+IA fibrinolytics versus MT 
and sICH with strata of different dose regimens applied 
(mixed effect model, estimate −0.15, 95% CI −0.48 to 0.19 
per mg, see online supplemental figure 4) for bubble plot). 
No excess mortality after additional treatment with IA fibri-
nolytics was found (OR 0.81, 95% CI 0.60 to 1.08, I2=0%; 
OR 0.90, 95% CI 0.63 to 1.29 for tPA only, figure 4). Further 
subgroup analyses and restriction to adjusted estimates for 
safety endpoints can be found in online supplemental infor-
mation 2.
Figure 2 Forest plot of summary odds ratios for sICH in patients with and without adjunctive administration of IAF during MT with strata of 
IVT before MT. (A) With intravenous tPA (IVT) before MT. (B) Without IVT MT. *For Anadani et al we used PH2 as sICH surrogate. IAF, intra- arterial 
fibrinolytics; IVT, intravenous thrombolysis; MT, mechanical thrombectomy; PH2, parenchymal hematoma type 2; sICH, symptomatic intracranial 
hemorrhage; tPA, tissue plasminogen activator; uPA, urokinase.
Figure 3 Forest plot of summary odds ratios for sICH comparing patients with bridging therapy, MT and added IAF to patients with direct MT 
and added IAF. *For Anadani et al we used PH2 as sICH surrogate. IAF, intra- arterial fibrinolytics; IVT, intravenous thrombolysis; MT, mechanical 
thrombectomy; PH2, parenchymal hematoma type 2; sICH, symptomatic intracranial hemorrhage; tPA, tissue plasminogen activator; uPA, urokinase.
 on M
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Functional outcome and angiographic efficacy
There was no difference in functional outcome (OR 1.08, 95% CI 
0.78 to 1.49, I2=35%) (online supplemental figure 5 and 6) or 
successful reperfusion (OR 0.85, 95% CI 0.66 to 1.29) (online 
supplemental figure 7) between patients treated with additional 
IA fibrinolytics and those without. The point estimate of reper-
fusion differed based on the degree of reperfusion bias (online 
supplemental figure 7) and on qualitative study- level analyses. 
The reporting of angiographic reperfusion improvement after 
added IA fibrinolytics was heterogeneous across the included 
studies, with some studies reporting improved angiographic 
perfusion (online supplemental table 2).
DISCUSSION
We found the following: (1) The quality of evidence regarding 
the relative benefits of additive IA fibrinolytics versus standard 
of care during contemporary MT is low and limited to obser-
vational data. (2) IA fibrinolytics are often not administered 
according to a standardized protocol, but with the following 
indications—after failed or incomplete MT, during MT at the 
discretion of the operator, and for treatment of emboli in new 
territories during MT. (3) In a highly selected subgroup, addi-
tional administration of IA fibrinolytics was not associated with 
a clear excess risk of sICH or 90 day mortality, but there is large 
uncertainty. (4) Considering adjusted estimates and qualitative 
angiographic efficacy analyses reported by some studies, IA fibri-
nolytics may improve reperfusion after failed or incomplete MT.
Frequency of IA fibrinolytics in contemporary MT
Currently it is unknown whether administration of IA fibrino-
lytics is safe when applied as additive to MT. In the MRCLEAN26 
and ESCAPE25 trials, additional use of IA thrombolysis was 
reported, although no subgroup analyses were available. Also 
in the THRACE trial, IA tPA was used to a maximum dose of 
0.3 mg/kg. Here, IA tPA was administered in 15/141 patients 
(10.6%) with a mean dose of 8.8 mg after full dose IV tPA, 
without significant difference regarding functional outcome 
between patients treated with or without additional tPA (7/15 
(46.7%) vs 64/126 (50.8%), p=0.76).27 Corroborating these 
findings, administration of IA fibrinolytics during or after MT 
also seems relatively common in clinical real- life practice outside 
randomized controlled trials according to recent survey data.18 19 
In the TREVO registry, IA tPA was administered in 28 of 65 
cases as a rescue therapy (43%)13 and IA tPA was used in 14% 
of patients harboring a middle cerebral artery occlusion treated 
with MT in in the STRATIS registry.12 Although not representa-
tive, the relative frequency of administering IA fibrinolytics was 
14.8% in patients treated with MT in our meta- analysis. Inter-
estingly, IA fibrinolytics were also administered after preceding 
treatment with intravenous thrombolysis, which was the case in 
51.6% of patients in this meta- analysis. In addition, the current 
review also shed light on indications for IA fibrinolytics, ranging 
from incomplete or failed MT to administration before or during 
stent- retriever deployment or as a treatment option for emboli 
to new territory.
Risk of sICH
We did not find a significant association between sICH and 
administration of IA fibrinolytics and there was no significant 
heterogeneity as to intravenous tPA pretreatment status or 
dose regimens applied (median range 4–13.25 mg). However, 
point estimates favored MT without IA and 95% confidence 
and prediction intervals were large and patients were highly 
selected (mostly small core patients included). Beside favorable 
patient selection, an overall lack of a clear association between 
the administration of IA fibrinolytics and increased risk of sICH 
may have several other reasons. First, improved reperfusion is 
generally associated with reduced rates of hemorrhagic transfor-
mations and sICH.6 34 35 Hence, improved reperfusion after IA 
fibrinolytics could counterbalance the potential increase of sICH 
after administration of IA fibrinolytics. Second, IA fibrinolytics 
were not administered in a randomized manner, and the compar-
ison of baseline characteristics revealed significant differences, 
some of which have been associated with an a priori lower risk 
of sICH in the IA fibrinolytics group, potentially leading to selec-
tion bias (eg, earlier presentation or younger age). Third, asso-
ciations may be weak when applied as low- dose adjunct to MT 
and larger sample sizes would be needed to detect a significant 
association. Lastly, we pooled different types of fibrinolytics and 
risk of sICH might differ, although previous studies suggested 
a comparable risk profile when administered intra- arterially.36
Some evidence on the safety of IA fibrinolytics as adjunct 
to MT is derived from the transition phase between first- and 
second- generation devices, and here results were contradictory 
and may thus not be easily transferable to current practice. In the 
SWIFT (Solitaire With the Intention For Thrombectomy) trial, 
Figure 4 Forest plot of unadjusted odds ratios for mortality at 3 months in patients with and without adjunctive administration of IAF during MT. 
*For Anadani et al we used PH2 as sICH surrogate. IAF, intra- arterial fibrinolytics; MT, mechanical thrombectomy; PH2, parenchymal hematoma type 2; 
sICH, symptomatic intracranial hemorrhage; tPA, tissue plasminogen activator; uPA, urokinase.
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rescue with IA thrombolysis was associated with an increased 
risk of bleeding (OR 12.1, 95% CI 1.082 to 134.5), although 
most bleedings occurred in the MERCI group and no analysis 
of sICH stratified for the use of additive IA fibrinolytics is avail-
able.37 In contrast, administration of IA tPA was associated with 
lower chances of PH (aOR 0.57, 95% CI 0.35 to 0.90) in a large 
heterogeneous cohort of patients treated with first- and second- 
generation devices in the USA.38
Angiographic efficacy
If IA fibrinolytics were administered in order to improve unsuc-
cessful or incomplete reperfusion, rates of successful reperfu-
sion tended to be lower than in the control group for obvious 
selection reasons. There was, however, no significant difference 
between the groups if low reperfusion bias studies were consid-
ered. Given that the reperfusion result is inherently associated 
with the indication to administer IA fibrinolytics, we think that 
a mere pooling of the rates of successful reperfusion across the 
groups is not advisable, which is why we added a qualitative 
analysis regarding reperfusion efficacy. Despite homogenous 
indications and ways of reporting, hints towards an improved 
angiographic reperfusion after the additive use of IA fibrinolytics 
were observed on an individual study level.
Outlook and future direction
Currently, we are aware of two trials evaluating IA fibrino-
lytics as adjunct to MT. In one small single- arm pilot trial from 
China (NCT04202458) patients will receive IA administration 
of 4 mg tenecteplase (TNK), which is continuously given after 
the first attempt of thrombectomy device pass for 30 min. The 
BRETIS- TNK (Boosting REcanalization of Thrombectomy for 
Ischemic Stroke by Intra- arterial TNK) trial will include 30 
patients. Currently the data on the safety and efficacy of IA TNK 
are sparse and limited to small observational studies39 or case 
reports40 and no data of IA TNK as adjunct to MT are available. 
The European randomized controlled trial CHOICE (CHemical 
OptImization of Cerebral Embolectomy in patients with acute 
stroke treated with mechanical thrombectomy) will evaluate 
the administration of IA fibrinolytics after incomplete (TICI2b) 
reperfusion with MT.41 In this trial, patients will be random-
ized to receive either a 30 min IA infusion with weight- adapted 
tPA or IA placebo. The study will enroll 200 patients, with an 
expected increase from TICI2b to TICI2c/3 of 60% in the exper-
imental arm and 5% in the placebo arm. Given reports synthe-
sized here, 60% improvement in the experimental arm seems 
high considering that one study reported 50% overall reperfu-
sion improvement, with only around 30% being TICI grade rele-
vant.33 However, the presented data provide some reasurrance 
that administration of IA fibrinolytics does not markly increase 
the risk of sICH in highly selected patients and when low dose 
regimens are applied.
Lastly, the data presented stress the need for a future standard-
ized reporting pattern when describing patients treated with IA 
fibrinolytics as adjunct to MT. This includes a precise description 
of indication, time- point of administration, dosage, and evalu-
ation of angiographic or follow- up perfusion efficacy. Further 
prospective, multicenter studies are urgently needed to elaborate 
the role of IA fibrinolytics in contemporary stroke MT.
Limitations
This study has several limitations, some related to potential 
sources of bias inherent to the included observational studies. 
In all included studies, indications for and administration of 
IA fibrinolytics was neither randomized nor standardized, thus 
prompting selection bias. Some studies provided adjusted anal-
yses (matching or logistic regression), which may have mitigated, 
but presumably could not entirely account for selection bias 
effects. Moreover, we pooled data on the occurrence of sICH, 
despite heterogeneous definitions. Angiographic efficacy anal-
ysis was limited to qualitative analysis, because heterogeneous 
indications and discrepant ways of reporting limited the useful-
ness of summary estimates. Lastly, new devices and different 
modes and combination of flow- arrest during MT have entered 
the market and clinical routine in recent years, thus potentially 
changing the need for and respective value of additional admin-
istration of IA fibrinolytics.
CONCLUSION
The quality of evidence regarding the relative benefits of addi-
tional IA fibrinolytics versus standard of care during contem-
porary MT is low and limited to observational data. In highly 
selected patients treated with MT ± preceding intravenous 
thrombolysis, additional administration of IA fibrinolytics (uPA 
or tPA) does not seem to increase the risk of sICH. Further 
studies evaluating its potential to improve reperfusion after 
incomplete or failed MT are warranted.
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